Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Webcast ImageWebcast
Q4 2018 Charles River Laboratories International, Inc. Earnings Conference Call (Replay)
02/13/19 at 8:30 a.m. ET

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.


News Releases

DateTitle 
02/13/19Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 GuidancePrinter Friendly Version
02/13/19Charles River Laboratories Signs Binding Offer to Acquire CitoxlabPrinter Friendly Version
01/30/19Charles River Laboratories and Toxys Enter Agreement to Offer ToxTracker® in North AmericaPrinter Friendly Version
01/17/19Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference CallPrinter Friendly Version
View More

Upcoming Events

There are currently no events scheduled.
View More

Stock Quote

CRL (common)
Price
$142.39
Change (%)
+ 0.72 (0.51%)
Volume
311,655
Exchange
NYSE
Data as of 02/21/19 4:02 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)